Aug 07, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
Acadia Q2 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth
ACAD reports encouraging second-quarter results as earnings and revenues beat estimates, driven by year-over-year growth in Nuplazid and Daybue sales.
Aug 07, 2025 • Motley Fool
SOMEWHAT-BULLISH
Acadia ( ACAD ) Q2 Revenue Rises 9%
Acadia Pharmaceuticals ( NASDAQ:ACAD ) , a neuroscience-focused biopharma company behind treatments for central nervous system diseases, reported its earnings for Q2 2025 on August 6, 2025. The most notable news was a slight beat on both GAAP earnings and revenue, driven by ongoing growth in its ...
Aug 06, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
Acadia Pharmaceuticals ( ACAD ) Tops Q2 Earnings and Revenue Estimates
Acadia (ACAD) delivered earnings and revenue surprises of +14.29% and +1.87%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Aug 05, 2025 • Zacks Commentary
NEUTRAL
Adaptive Biotechnologies ( ADPT ) Reports Q2 Loss, Beats Revenue Estimates
Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of +29.17% and +18.47%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Aug 05, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
Catalyst Pharmaceutics to Report Q2 Earnings: What's in the Cards?
CPRX gears up to report Q2 results as Firdapse sales rise, Agamree grows, and Fycompa faces a post-patent dip.
Aug 04, 2025 • Zacks Commentary
NEUTRAL
Recursion Pharmaceuticals to Report Q2 Earnings: What's in the Cards?
RXRX eyes Q2 earnings beat despite past misses, with a refocused pipeline and new data updates on key drug candidates.